• Psora 4 in Context: Kv1.3 Blocker Pharmacology and Immune Mo

  2026-06-29

  Explore the molecular pharmacology of Psora 4, a potent Kv1.3 blocker, with a focus on its nuanced mechanism in effector memory T cell inhibition and the impact of channel subunit composition. This article offers advanced guidance for immunological assay design, bridging recent mechanistic insights with practical research applications.

• VX-765: Advancing Caspase-1 Inhibition in Inflammation Resea

  2026-06-29

  VX-765’s selective caspase-1 inhibition enables targeted dissection of IL-1β and IL-18 signaling without broad cytokine suppression, making it indispensable in inflammation and pyroptosis research. With robust solubility and oral bioavailability, it empowers streamlined workflows in disease models from autoimmunity to infectious disease.

• SP2509: Advanced LSD1 Antagonism for Cancer Epigenetics Rese

  2026-06-28

  Explore how SP2509, a potent Lysine-specific demethylase 1 antagonist, enables next-generation cancer epigenetics studies through selective mechanism and practical workflow insights. This article uniquely integrates mechanistic depth with actionable protocols for researchers.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Proto

  2026-06-27

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted protein degradation during extraction and sample handling, especially where EDTA would interfere with assays sensitive to divalent cations. It is especially suited to workflows such as Western blotting, kinase assays, and co-immunoprecipitation, but is not appropriate where DMSO intolerance or non-protease-related degradation dominates.

• 6-FAM SE: Durable Fluorescent Labeling for Molecular Workflo

  2026-06-26

  6-FAM SE (6-Carboxyfluorescein N-hydroxysuccinimide ester) empowers robust, hydrolysis-resistant fluorescent labeling of DNA, proteins, and peptides, setting a new standard for gene sequencing and advanced molecular biology. Applied best practices and troubleshooting insights ensure precise, reproducible results for both classic and cutting-edge assays.

• PP 3: A Validated Negative Control for Src Kinase Pathway Re

  2026-06-26

  PP 3 (1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine) is a research use only chemical from APExBIO, serving as a negative control for Src kinase inhibition studies. It enables accurate differentiation of specific Src pathway effects and ensures experimental validity in cell signaling research.

• Disulfiram as a Synthetic Lethality Tool in APC-Deficient Ca

  2026-06-25

  Explore how Disulfiram, a dopamine β-hydroxylase inhibitor, uniquely enables synthetic lethality in APC-deficient cancers by targeting ALDH2 and proteasome pathways. This article reveals advanced assay guidance and critical insights for cancer research.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-06-25

  Shapira-Netanelov et al. introduce a patient-derived gastric cancer assembloid model that integrates tumor organoids with matched stromal cell subpopulations, capturing the cellular and molecular complexity of primary tumors. This approach enables more physiologically relevant studies of tumor microenvironment, drug response, and mechanisms of resistance, with significant implications for personalized therapy development.

• ECL Western Blotting Substrate: Technical Use and Protocols

  2026-06-24

  ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of proteins conjugated to horseradish peroxidase in chemiluminescent Western blot assays. It is recommended for workflows in molecular biology, cancer biology, and signal transduction pathway research, but is not appropriate for assays requiring fluorescent or radioisotopic detection.

• Neticonazole Hydrochloride: Reliable Solutions for Antifunga

  2026-06-23

  This article explores how Neticonazole Hydrochloride (SKU C8715) addresses common laboratory challenges in antifungal and oncology research. Through scenario-based Q&A, we highlight data-backed best practices, protocol optimization, and product reliability for cell viability, cytotoxicity, and exosome inhibition workflows. Researchers will gain actionable strategies for leveraging this imidazole antifungal in both mycology and cancer assay systems.

• Selective β1 Blockade Preserves Hematopoietic Regeneration P

  2026-06-23

  This study demonstrates that nonselective β-adrenergic receptor inhibitors impair hematopoietic regeneration after transplantation, while β1-selective agents like Metoprolol Tartrate do not. The findings highlight the crucial role of β-blocker selectivity in both clinical management and experimental modeling of hematopoietic recovery.

• Angiotensin II in Translational Research: Workflows & Troubl

  2026-06-22

  Angiotensin II empowers high-fidelity cardiovascular modeling, from hypertension mechanism studies to vascular smooth muscle cell hypertrophy research. This guide translates recent mechanistic discoveries and peer-reviewed protocols into actionable workflows and troubleshooting strategies, maximizing the value of APExBIO’s Angiotensin II for research.

• Glabridin-Gold(I) Complex Targets TrxR/MAPK to Boost Tumor I

  2026-06-22

  This study introduces a glabridin-gold(I) (6d) complex as a novel immunomodulatory agent that enhances antitumor immunity by dual inhibition of TrxR and MAPK pathways. By promoting dendritic cell maturation and reducing immunosuppressive cells, 6d demonstrates promising synergy for improving cancer immunotherapy outcomes.

• Apicidin: Advanced Histone Deacetylase Inhibitor Workflows

  2026-06-21

  Apicidin, a potent and selective histone deacetylase inhibitor, offers unique advantages for probing epigenetic mechanisms and anti-proliferative effects in cancer and reproductive biology. Leverage optimized protocols and troubleshooting insights to unlock robust assay performance and translational research breakthroughs.

• SB 202190: Precision p38 MAP Kinase Inhibitor in Cancer and

  2026-06-20

  SB 202190 stands out as a highly selective p38 MAP kinase inhibitor, empowering researchers to unravel the complexities of MAPK-mediated inflammation and tumor immune evasion. Its nanomolar potency, proven reproducibility in both organoid and apoptosis assays, and broad compatibility with disease models establish it as a cornerstone for translational studies.

466 records 14/32 page Previous Next First page 上5页 1112131415 下5页 Last page